SCHOTT Pharma AG & Co. KGaA
ISIN: DE000A3ENQ51
WKN: A3ENQ5
04 December 2024 11:00AM

EQS-News: Next-level efficiency and sustainability: SCHOTT Pharma unveils innovative nest design for ready-to-use cartridges

SCHOTT Pharma AG & Co. KGaA · ISIN: DE000A3ENQ51 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 2044183

EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Market Launch
Next-level efficiency and sustainability: SCHOTT Pharma unveils innovative nest design for ready-to-use cartridges

04.12.2024 / 11:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Next-level efficiency and sustainability: SCHOTT Pharma unveils innovative nest design for ready-to-use cartridges

  • New diamond-shaped nest design for ready-to-use (RTU) cartridges boosts efficiency in pharmaceutical filling processes by up to 67% and significantly reduces CO2 emissions by close to 25% in the supply chain for 1.5 ml RTU cartridges.
  • Depending on the specifications of the cartridges, the new nest increases packing density by up to 60% while improving stability and maintaining the same external nest dimensions.
  • With the new nest, pharma companies benefit from faster fill-and-finish operations of critical medications, including GLP-1, insulin, and hormone therapies.

 

SCHOTT Pharma, a pioneer in drug containment and delivery solutions, announces the launch of its groundbreaking nest design for ready-to-use (RTU) cartridges known as cartriQ®. The new nest retains its external dimensions, while the cartridges are fixated in diamond-shaped holes instead of round ones. This optimized configuration significantly increases the packing density by up to 60% while improving stability, which is crucial as the cartridges remain in the nest during the entire filling process. “With this revolutionary product, we are proactively addressing one of the key factors in reducing costs for pharmaceutical companies and reorganizing their value chain. Our new nest for RTU cartridges not only enhances operational efficiency by up to 67% when using 1.5 ml cartridges, but also significantly contributes to sustainability efforts in the industry," said Andreas Reisse, CEO of SCHOTT Pharma. "We have received positive feedback from our customers so far," he adds, citing the case of a Big Pharma company where the new nest for 3 ml RTU cartridges has also been optimized for high packaging density using the same approach. In the long term, this change can save a pharma company a considerable amount of CO2 per year.

SCHOTT Pharma’s new nest is available For Human Use (FHU) and is manufactured at the company’s production site in St. Gallen, Switzerland with the outlook of further sites adopting it in the future. It is a complete solution that enhances the efficient filling of high-quality drugs, such as GLP-1, insulin, and hormone therapies. Depending on the requirements of the drug and therefore the format of the cartridge, SCHOTT Pharma managed to fit as many as 160 RTU cartridges in one nest when using the 1.5 ml cartriQ® format while ensuring highest quality and stability.

Driving high-value solutions to meet customer needs

The complete platform of cartriQ® sterile cartridges ranges from small to large filling volumes of 1.5 ml to 20 ml. As an RTU solution, the cartridges are crimped, pre-washed, depyrogenated, siliconized, and steam sterilized. This preparation enables CDMOs and pharma companies to commence the filling process immediately, bypassing the need to manage these preliminary steps themselves. As part of SCHOTT Pharma’s high-value solutions (HVS) portfolio, these cartridges and the new nest exemplify the company’s commitment as a reliable partner to the pharma industry, providing premium, innovative solutions that meet the customers’ needs.

 

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of over 4,600 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the MDAX. It is part of SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 899 million in the fiscal year 2023. Further information at www.schott-pharma.com.

 

Press contact:

Joana Kornblum
Media Relations
Tel.: +49 151/29223552 
E-Mail: joana.kornblum@schott.com   
 

Jasko Terzic, CFA 
Senior Manager Investor Relations 
E-Mail: ir.pharma@schott.com  



04.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SCHOTT Pharma AG & Co. KGaA
Hattenbergstraße 10
55122 Mainz
Germany
ISIN: DE000A3ENQ51
WKN: A3ENQ5
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
EQS News ID: 2044183

 
End of News EQS News Service

2044183  04.12.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2044183&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 0,00 0,00 584,23 648,67 821,14 898,60 957,09
EBITDA1,2 0,00 0,00 131,94 164,10 219,73 239,00 257,55
EBITDA-Margin3 0,00 0,00 22,58 25,30 26,76 26,60 26,91
EBIT1,4 0,00 0,00 98,22 127,66 164,38 192,38 192,58
EBIT-Margin5 0,00 0,00 16,81 19,68 20,02 21,41 20,12
Net Profit (Loss)1 0,00 0,00 77,63 101,17 125,85 151,93 150,35
Net-Margin6 0,00 0,00 13,29 15,60 15,33 16,91 15,71
Cashflow1,7 0,00 0,00 104,40 132,21 182,12 181,65 225,33
Earnings per share8 0,00 0,00 0,51 0,67 0,83 1,01 0,99
Dividend per share8 0,00 0,00 0,00 0,00 0,12 0,15 0,18
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: Ernst & Young

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Schott Pharma
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
A3ENQ5 DE000A3ENQ51 AG & Co. KGaA 3.662,95 Mio € 28.09.2023 9F2C268V+9J
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
22,52 28,92 0,78 28,68 4,78 16,26 3,83
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
0,12 0,15 0,18 0,74%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
04.02.2025 13.02.2025 15.05.2025 12.08.2025 12.12.2024
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+1,08%
24,32 €
ATH 42,40 €
-14,06% -23,83% -27,62% -27,19% -9,93%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL